1. Schottenfeld D: Gastrointestinal cancer: epidemiology. In Gastrointestinal Oncology: Principles and Practice. Edited by Kelsen DP, Daly JM, Levin B, et al. Philadelphia: Lippincott, Williams & Wilkins; 2002:3–24.
2. Berlin J: New directions in the treatment of advanced colorectal cancer. Oncology (Huntingt) 2001, 15(Suppl 5):27–30.
3. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593–1611.
4. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3–9. A comprehensive review of the rationale and application of EGFR blockade as an anticancer strategy, including insights into the mechanisms of C225.
5. Cunningham D, Humblet Y, Siena D, et al.: Cetuximab alone or in combination with irinotecan in patients with epidermal growth factor receptor positive, irinotecan- refractory metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:1012.